Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155979 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KMT2AL3MBTL1NPC1MEN1 | |
| SCHEMBL5549224 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KMT2AL3MBTL1NPC1MEN1 | |
| SCHEMBL6155476 | 0.79 | CYP1A2 (0.46) | ALDH1A1KMT2AL3MBTL1NPC1MEN1 | |
| SCHEMBL6154112 | 0.76 | ALDH1A1 (0.42) | ALDH1A1KMT2AL3MBTL1NPC1MEN1 | |
| SCHEMBL8141137 | 0.76 | TDP1 (0.46) | ALDH1A1KMT2AL3MBTL1LMNA | |
| SCHEMBL6154475 | 0.76 | PTGS2 (0.43) | ALDH1A1KMT2ANPC1MEN1RAB9A | |
| SCHEMBL6153863 | 0.71 | PPARG (0.35) | KMT2AL3MBTL1MEN1LMNAMAPT | |
| SCHEMBL6155138 | 0.70 | NPC1 (0.43) | KMT2AL3MBTL1NPC1RAB9ALMNA | |
| SCHEMBL6155298 | 0.70 | ALDH1A1 (0.44) | ALDH1A1KMT2AL3MBTL1NPC1MEN1 | |
| SCHEMBL7897440 | 0.69 | ALDH1A1 (0.37) | ALDH1A1KMT2AL3MBTL1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | claimed |
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | KELLEHER JUDITH A (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6433008-B1 | TREATING PARKINSON*S, ALZHEIMER*S, AUTOIMMUNE AND RHEUMATIC DISEASES; HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEMENTIA, AND INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | ALDH1A1 410/4885KMT2A 4081/4885L3MBTL1 3663/4885 |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | ALDH1A1 499/4885KMT2A 3999/4885L3MBTL1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.